Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AAV.7m8-aflibercept
ADVM-022 · 2 trials · 2 indications
BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS)
| Arm | Type | Description |
|---|---|---|
| Dose 1 | EXPERIMENTAL | A single intravitreal injection of ADVM-022 2E11 vg/eye |
| Dose 2 | EXPERIMENTAL | A single intravitreal injection of ADVM-022 6E10 vg/eye |
| Name | Type | Description |
|---|---|---|
| ADVM-022 | GENETIC | A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens |
Inclusion Criteria: * Male or female participants, ≥ 50 years of age * Willing and able to provide written, signed informed consent for this study * Demonstrated a meaningful response to anti-VEGF therapy * Participants must be under active anti-VEGF treatment for wet AMD and received a minimum of ...
ADVM-022 is an investigational gene therapy being developed for neovascular age-related macular degeneration, also called wet AMD. It is designed as an intravitreal treatment for patients with this form of retinal disease, which is the condition studied across its clinical program.
ADVM-022 is being developed by Adverum Biotechnologies, Inc., a company that trades under the ticker ADVM. Adverum is the sponsor of the clinical program evaluating the gene therapy in patients with neovascular age-related macular degeneration.
ADVM-022 is in Phase 2 clinical development. Its Phase 2 study is the LUNA trial, which is active and not currently recruiting. An earlier Phase 1 study of ADVM-022 in wet AMD has been completed. ADVM-022 is investigational and has not been approved by the FDA.
ADVM-022 has been studied in two clinical trials. The Phase 2 LUNA trial, NCT05536973, is active and not recruiting and enrolled 69 treatment-experienced patients with neovascular age-related macular degeneration across the United States, France, and the United Kingdom. The completed Phase 1 trial, NCT03748784, enrolled 30 patients in the United States.
Yes. The Phase 2 LUNA trial of ADVM-022, NCT05536973, is a randomized, double-blind, controlled study. It enrolled 69 treatment-experienced patients with neovascular age-related macular degeneration who were at least 50 years of age, and it is active but no longer recruiting participants.
ADVM-022 is a gene therapy administered by intravitreal injection, meaning it is delivered into the eye. It is being developed for neovascular age-related macular degeneration and is evaluated in clinical trials that enroll patients with wet AMD who have already received treatment.